The present invention generally relates to therapeutic methods, and particularly to a biomarker-based method of treating non-small cell lung cancer using an FGFR inhibitor.
Materials and Methods – Soft-Agar Assay:
Cells were suspended in growth media containing 10% FCS and 0.6% agar and plated in triplicate on 50 μl solidified growth medium (10% FCS; 1.0% agar). Growth medium containing indicated compound concentrations was added on top. Colonies were analyzed using the Scanalyzer imaging system (Lemnatec, Germany).